Sep 2026· Clinical and Translational Radiation Oncology· Vol 62, pp. 101281· 0 citations· 31 references
Medicine
TL;DR
The findings suggest that the 36.25-Gy regimen may be non-inferior to 40 Gy for EFS and may be associated with fewer grade 4 toxicities and better urinary QOL and should be considered hypothesis-generating.
Abstract
Background This study aimed to determine whether 36.25 Gy was inferior to 40 Gy in terms of prostate-specific antigen (PSA) recurrence following stereotactic body radiation therapy (SBRT) for prostate cancer. Methods We retrospectively reviewed the medical records of 863 consecutive patients with prostate cancer treated at a single institution between 2016 and 2025. Propensity score (PS) matching based on age, pre-treatment PSA level, biopsy Gleason score, clinical T-stage, National Comprehensive Cancer Network (NCCN) risk classification, and concomitant androgen-deprivation therapy (ADT) yielded 530 patients for analysis. Patients received SBRT at a total dose of 36.25 or 40 Gy in five fractions administered every other day. The prespecified non-inferiority margin was a hazard ratio of 1.40. Results After PS matching, no significant differences remained in baseline characteristics that had differed significantly between the two groups before matching. In the 36.25-Gy and 40-Gy groups, respectively, 16 and 10 PSA recurrences and 18 and 10 deaths occurred. Four PSA recurrences (15%) occurred over 5 years. The 5-year event-free survival (EFS) rates were 90% with 36.25 Gy and 88% with 40 Gy (p = 0.37). The hazard ratio for EFS with 36.25 Gy versus 40 Gy was 0.76 (95% confidence interval [CI], 0.42–1.39; p = 0.37). The 5-year PSA recurrence-free rates were 95% and 93%, respectively (p = 0.76). Among the 298 patients receiving 36.25 Gy, grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities occurred in 2.3% and 1.3%, respectively. Among the 565 patients receiving 40 Gy, grade 3 or GI toxicity occurred in 1.9%, and grade ≥ 3 GU toxicity occurred in 0.8%. No grade 5 toxicity occurred. Urinary and bowel quality of life (QOL) scores decreased at 1 month and returned to near-baseline levels by 3 months. Conclusions In this retrospective study, the findings suggest that the 36.25-Gy regimen may be non-inferior to 40 Gy for EFS and may be associated with fewer grade 4 toxicities and better urinary QOL. Given the retrospective design, these findings should be considered hypothesis-generating.
BACKGROUND
Stereotactic body radiotherapy has become an established treatment option for localised prostate cancer. However, real-world evidence from routine clinical practice remains limited, particularly in cohorts that include older patients. We therefore report long-term outcomes and treatment-related adverse event...
Atsuto Katano, Hideomi Yamashita· Journal of Medical Imaging a...· 0 citations
The incidence of prostate adenocarcinoma (PCa) increases with age. Stereotactic body radiotherapy (SBRT) is a curative option; however, the evidence in elderly patients remains limited. This single-institution retrospective cohort study included consecutive patients aged ≥80 years with localized PCa treated with defini...
Purpose Salvage high-dose-rate brachytherapy (sHDR-BT) is an effective option for radiorecurrent prostate cancer. This study aimed to compare the efficacy and toxicity of two sHDR-BT fractionation schedules and identify factors associated with treatment outcomes. Methods and Materials We retrospectively analyzed 223 pa...
Magdalena Stankiewicz, Agata Wilk, M. Krzempek et al.· Advances in Radiation Oncolo...· 0 citations
Stereotactic body radiotherapy (SBRT/SABR) is a curative treatment for early-stage lung cancer in patients unsuitable for surgery. While tumor laterality is routinely considered in surgical decision-making, its relevance to outcomes after SBRT remains unclear. This study evaluated clinical outcomes after SBRT and...
P. Burkoň, I. Selingerová, M. Slávik et al.· Radiation Oncology· 0 citations
Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.
Z. El Kouzi, M. Rooney, Adam B. Samman et al.· Brachytherapy· 0 citations
OBJECTIVES
Optimal dose fractionation of stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer (NSCLC) remains unclear. This population-based study compares outcomes and toxicities of single-fraction (SF) versus multi-fraction (MF) SABR.
METHODS
All patients in British Columbia, Canada w...
K. A. Aguirre-Meneses, S. Baker, J. Callueng et al.· Radiotherapy and Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.